Sarepta Therapeutics (SRPT) : Zacks Investment Research ranks Sarepta Therapeutics (SRPT) as 3, which is a Hold recommendation. 3 research analysts consider that the stocks fundamentals point to a bright future, hence they rate the stock as a Strong Buy. 1 other analysts are mildly bullish on the stock and favor a Buy. Not everyone is convinced about the stocks future, hence, the stock receives 1 Sell recommendation. 3 more believe that the stock has more downside risks, hence they propose a Strong Sell. A total of 5 analysts believe that the stock has a limited upside, hence they advise a Hold. The average broker rating of 13 research analysts is 3, which indicates as a Hold.
Sarepta Therapeutics (SRPT) : Average target price received by Sarepta Therapeutics (SRPT) is $22.27 with an expected standard deviation of $17.24. The most aggressive target on the stock is $60, whereas the most downbeat target is $4. 11 financial analysts are currently covering the stock.
Shares of Sarepta Therapeutics, Inc. rose by 5.21% in the last five trading days and 10.86% for the last 4 weeks. Sarepta Therapeutics, Inc. is up 42.3% in the last 3-month period. Year-to-Date the stock performance stands at -31.99%. Sarepta Therapeutics (NASDAQ:SRPT): stock turned positive on Tuesday. Though the stock opened at $26.11, the bulls momentum made the stock top out at $26.38 level for the day. The stock recorded a low of $25.75 and closed the trading day at $26.24, in the green by 0.50%. The total traded volume for the day was 1,436,090. The stock had closed at $26.11 in the previous days trading.
Sarepta Therapeutics, Inc. is a biopharmaceutical company. The Company is focused on the discovery and development of unique ribonucleic acid (RNA-targeted therapeutics for the treatment of rare, infectious and other diseases. The Company is primarily focused on advancing the development of its potentially disease-modifying Duchenne Muscular Dystrophy (DMD) drug candidates, including its lead DMD product candidate, eteplirsen, which is an antisense PMO therapeutic in Phase III clinical development for the treatment of individuals with DMD who have an error in the gene coding for dystrophin that is amenable to skipping exon 51. The Company is also developing therapeutics using its technology for the treatment of drug-resistant bacteria and infectious, rare and other human diseases.